The Enhanced Games — tech’s steroid extravaganza — didn’t pay off, as company posts $60 million loss
The Enhanced Games, a controversial sports event allowing athletes to compete while using performance-enhancing drugs normally banned in professional sport, has proved a commercial failure as well as a competitive one. Its organiser, Enhanced Group, has reported a net loss of nearly $62 million for the second quarter, largely attributable to hosting the games in Las Vegas in May, which produced little in the way of athletic spectacle beyond a single swimming world record. The result raises doubts over the company's stated ambition to make the event an annual fixture, given the scale of the losses involved.
Enhanced Group, founded in 2023 and backed by figures including Peter Thiel, floated earlier this year at a $1.2 billion valuation and primarily sells FDA-approved treatments such as peptides, testosterone injections and GLP-1 weight-loss drugs through a telehealth platform. Of the $17.7 million it generated last quarter, most came from games-related sponsorships rather than its core telehealth business, about which little further detail was disclosed. The company appears to be shifting strategy, promoting a cheaper online series called Enhanced Breakers, even as the wider performance-medicine and peptide industry gains momentum, aided by regulatory moves under the Trump administration's FDA to reclassify certain long-restricted substances.
- Enhanced Games' organiser posted a $62 million quarterly loss
- The Las Vegas event was both a competitive and commercial flop
- Company may pivot to cheaper online series, Enhanced Breakers
New here? Start with this
The Enhanced Games is a sports competition, launched this year, that lets athletes take performance-enhancing drugs normally banned in mainstream sport, on the argument that closer medical supervision makes this safer than clandestine doping. It is run by Enhanced Group, a company founded in 2023 with backing from prominent tech investors including Peter Thiel, and which listed on the stock market earlier this year at a valuation of $1.2 billion.
Beyond the games themselves, Enhanced Group's main business is a telehealth platform selling treatments such as peptides, testosterone and weight-loss drugs, an industry that has been getting a regulatory boost under the Trump administration. The company staged its first live event in Las Vegas in May, pitching it as a potential annual fixture and a new kind of made-for-attention sporting spectacle.
The venture matters because it sits at the crossroads of sport, medicine and Silicon Valley-style investment, testing whether a business built around openly doped competition can attract audiences, sponsors and reliable revenue in the way its backers hoped.
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Supporters of the venture argue that ambitious new sporting formats often take years and heavy upfront investment before they find a stable footing, and that a single loss-making quarter dominated by one-off launch costs in Las Vegas should not be read as a verdict on the underlying concept. They would note the company retains a diversified revenue base through its telehealth business, is adapting sensibly by trialling a cheaper online format in Enhanced Breakers, and is operating in a regulatory and cultural climate increasingly open to performance medicine, peptides and hormone therapies. For these advocates, the deeper value at stake is athlete autonomy and honesty: rather than forcing competitors into clandestine doping, an openly enhanced event lets athletes make informed choices about their own bodies under medical supervision and transparent rules.
The case against
Sceptics would argue that the scale of the loss simply confirms what critics predicted from the outset: that an event built around banned performance-enhancing drugs was always a shaky commercial and ethical proposition rather than a genuine sporting innovation. They would point out that the Las Vegas games produced barely any athletic spectacle to justify the risk, that most revenue came from sponsorship hype rather than sustained demand for either the games or the core telehealth offering, and that the swift pivot to a cheaper format suggests the original model was unsustainable. For these critics, the values at stake are the integrity of fair competition and athlete welfare, and they would see the financial stumble as a healthy market signal against normalising practices long restricted for good medical and safety reasons.